In an effort to address how CDK4 inhibition enhances therapy vulnerability, Chen-Kiang developed a phase I clinical trial of palbociclib, findings of ...
from Google Alert - vulnerability https://ift.tt/2KxFt1t
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment